Nonselective Beta-blockers and HCC Risk Among Cirrhotic Patients Nonselective Beta-blockers and HCC Risk Among Cirrhotic Patients

Might nonselective beta-blockers such as carvedilol, nadolol, and propranolol decrease the risk of hepatocellular carcinoma among patients with cirrhosis?Alimentary Pharmacology & Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news